RIPK2-IN-1

CAS No. 1423186-80-4

RIPK2-IN-1( GSK2983559 | GSK-2983559 | GSK 2983559 | RIPK2-IN-1 | RIPK2 IN 1 )

Catalog No. M11784 CAS No. 1423186-80-4

A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 87 In Stock
10MG 140 In Stock
25MG 259 In Stock
50MG 484 In Stock
100MG 700 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    RIPK2-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.
  • Description
    A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.(In Vitro):GSK2983559 active metabolite is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor interacting protein-2 (RIP2) kinase, which is also referred to as CARD3, RICK, CARDIAK, or RIPK2, is a TKL family serine/threonine protein kinase involved in innate immune signaling. RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region. The CARD domain of RIP2 kinase mediates interaction with other CARD-containing proteins, such as NODI and NOD2. NODI and NOD2 are cytoplasmic receptors which play a key role in innate immune surveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated by specific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) and muramyl dipeptide.
  • In Vitro
    GSK2983559 active metabolite is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor interacting protein-2 (RIP2) kinase, which is also referred to as CARD3, RICK, CARDIAK, or RIPK2, is a TKL family serine/threonine protein kinase involved in innate immune signaling. RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region. The CARD domain of RIP2 kinase mediates interaction with other CARD-containing proteins, such as NODI and NOD2. NODI and NOD2 are cytoplasmic receptors which play a key role in innate immune surveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated by specific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) and muramyl dipeptide.
  • In Vivo
    ——
  • Synonyms
    GSK2983559 | GSK-2983559 | GSK 2983559 | RIPK2-IN-1 | RIPK2 IN 1
  • Pathway
    Apoptosis
  • Target
    RIP kinase
  • Recptor
    RIP2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1423186-80-4
  • Formula Weight
    458.5538
  • Molecular Formula
    C21H22N4O4S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 32 mg/mL
  • SMILES
    O=S(C1=CC2=C(NC3=CC=C(SC=N4)C4=C3)N=CN=C2C=C1OCCO)(C(C)(C)C)=O
  • Chemical Name
    Ethanol, 2-[[4-(5-benzothiazolylamino)-6-[(1,1-dimethylethyl)sulfonyl]-7-quinazolinyl]oxy]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Linda N. Casillas, et al. Prodrugs of amino quinazoline kinase inhibitor. PCT Int. Appl. (2014), WO 2014043446 A1 20140320.
molnova catalog
related products
  • GSK547

    GSK547 (RIP1i, GSK 547) is a highly selective and potent inhibitor of RIP1 kinase that robustly targets RIP1 in vivo.

  • RIPK1-IN-4

    RIPK1-IN-4 is a potent and selective type II kinase receptor interacting protein 1 (RIP1) kinase inhibitor and binds to a DLG-out inactive form of RIP1 (IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase).

  • Sibiriline

    A specific competitive RIPK1 inhibitor with IC50 of 1.03 uM, 100-fold less potent for RIPK3.